Get the Stockscreener App
1.47
14.04%
-0.24
Propanc Biopharma Inc stock is traded at $1.47, with a volume of 235.58K.
It is down -14.04% in the last 24 hours and down -28.29% over the past month.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
See More
Previous Close:
$1.71
Open:
$1.66
24h Volume:
235.58K
Relative Volume:
0.08
Market Cap:
$3.35M
Revenue:
-
Net Income/Loss:
$-18.36M
P/E Ratio:
-0.0443
EPS:
-33.1925
Net Cash Flow:
$-4.29M
1W Performance:
-39.51%
1M Performance:
-28.29%
6M Performance:
-91.83%
1Y Performance:
+0.00%
1-Day Range:
$1.41
$1.68
1-Week Range:
$1.41
$2.39
52-Week Range:
$1.30
$234.00
Propanc Biopharma Inc Stock (PPCB) Company Profile
Name
Propanc Biopharma Inc
Sector
Industry
Phone
61-03-9882-0780
Address
302/6 BUTLER STREET, CAMBERWELL, VICTORIA
Compare PPCB vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PPCB
Propanc Biopharma Inc
|
2.87 | 244.39K | 0 | 0 | 0 | 0.00 |
MOBBW
Mobilicom Limited Warrants
|
2.38 | 3.16B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
6.54 | 425.01M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.26 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.909 | 269.09M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
46.61 | 0 | 0 | 0 | 0 | 0.00 |
Propanc Biopharma Inc Stock (PPCB) Latest News
Propanc Biopharma Ord Shs (PPCB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PPCB stock surges over 200% just days after implementing reverse share split – what’s driving today’s smashing rally? - MSN
Propanc CEO tours European manufacturing facility for drug production - Investing.com UK
Propanc CEO visits European manufacturing facility for PRP production - Investing.com
Inside Propanc's plan to make a cancer drug for human study in Australia - Stock Titan
Nasdaq most active stocks: - MSN
PPCB Should I Buy - Intellectia AI
Propanc Biopharma (PPCB) Surges 80% as Trading Volume SpikesVOLD Alert - newsline.com
Top Midday Gainers - Moomoo
Trending Industry Today: Propanc Biopharma Leads Gains In ETH-Holding Companies Stocks - Moomoo
Trending Industry Today: Propanc Biopharma Leads Gains In Crypto Treasury Stocks - Moomoo
Top movers analysis one hour before the close of the markets on 2026-06-11: top gainers and losers in today's session. - ChartMill
These stocks are the most active in today's session - ChartMill
PPCB Stock Surges Over 200% Just Days After Implementing Reverse Share Split – What’s Driving Today’s Smashing Rally? - Asianet Newsable
Clinical-Stage Biotech Rockets 308% After $5M Buyback and Phase 1 Cancer-Trial Path - The Globe and Mail
Propanc Biopharma authorizes $5M share buyback program; shares surge - MSN
Propanc Biopharma, Inc. authorizes a Buyback Plan. - marketscreener.com
Propanc Biopharma, Inc. announces an Equity Buyback for $5 million worth of its shares. - marketscreener.com
Propanc Biopharma rockets after announcing $5M share repurchase program - Quiver Quantitative
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React - TechStock²
Propanc Biopharma Authorizes $5 Million Stock Buyback Program; Shares Jump - marketscreener.com
Trending Stocks Today | Propanc Biopharma Surges 282.95% - Moomoo
PPCB Stock Explodes As PRP Trial Plans Heat Up - StocksToTrade
PPCB Stock Pops As Propanc Biopharma Advances PRP Trials - timothysykes.com
Propanc Biopharma authorizes $5 million stock buyback program - Investing.com
Propanc Biopharma authorizes $5 million stock buyback program By Investing.com - Investing.com Australia
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program - The Manila Times
Cancer-drug developer Propanc sets aside $5M to buy its own stock - Stock Titan
Morning Market Movers: GLXG, PPCB, DSY, VSME See Big Swings - RTTNews
Dow Jumps Over 250 Points; US Initial Jobless Claims Rise - Sahm
Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain - markets.businessinsider.com
Propanc Biopharma's CEO Attends Keynote Address on Aging Science at University of Granada Event - Quiver Quantitative
How an ageing-science keynote ties into Propanc’s cancer trial - Stock Titan
Propanc Biopharma’s CEO Attends Keynote Address, 'Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain - The Manila Times
PPCB - Finviz
PPCB News | PROPANC BIOPHARMA INC (NASDAQ:PPCB) - ChartMill
Propanc Biopharma (PPCB) Edges Lower Amid Biotech VolatilityBreakout Confirmation - thelegaladvocate.com
Propanc Biopharma (PPCB) Holds Near Support as Slight Decline Signals CautionSuperTrend Flip - The Legal Advocate
PPCB Stock Price, Quote & Chart | PROPANC BIOPHARMA INC (NASDAQ:PPCB) - ChartMill
Propanc Biopharma (PPCB) Earnings Outlook: Key Metrics for Q3 2025Post-Announcement Reaction - Newser
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade - The Manila Times
Propanc Biopharma to file CTA in Australia for phase 1b study in 30-40 advanced cancer patients - marketscreener.com
Propanc Biopharma, Inc. CEO Forecasts Medical Breakthroughs Against Pancreatic Cancer Over Next Decade - Quiver Quantitative
Propanc pancreatic cancer drug saw 3 of 4 patients outlive life expectancy - Stock Titan
Propanc engages CDMO for GMP manufacture of cancer drug PRP By Investing.com - Investing.com Australia
Propanc engages CDMO for GMP manufacture of cancer drug PRP - Investing.com UK
Propanc Biopharma engages European CDMO for GMP production of PRP - TipRanks
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 3040 Advanced Cancer Patients - The Manila Times
Once-weekly proenzyme cancer therapy nears first tests in humans - Stock Titan
Propanc Biopharma (PPCB) Stock: Up +21.18%, Key Resistance at $2.16 2026-05-18Sector Analysis - newser.com
Propanc Biopharma Inc Stock (PPCB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):